Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 71

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 71
---
 that funds the federal government through March 14, 2025.

<div align='center'>45</div>

Separately, in response to
the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities,
and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently,
on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to
a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory
activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities.
Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19
pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities
from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the
FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect
on our business.

Risks Related to this Offering and Investment in Our Ordinary Shares

An active, liquid and orderly trading market for our Ordinary Shares may not develop, which may inhibit the ability of our shareholders to sell Ordinary Shares following this offering.

Prior to this offering there
has been no public market for our Ordinary Shares. An active, liquid or orderly trading market in our Ordinary Shares may not develop
upon completion of this offering, or if it does develop, it may not be sustained. The lack of an active market may impair your ability
to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also
reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital in the future by selling
shares and may impair our ability to acquire other companies by using our shares as consideration.

The market price of our Ordinary Shares may be volatile, which could result in substantial losses for investors purchasing shares in this offering.

The initial public offering
price for the Ordinary Shares will be determined through negotiations with the underwriters. The initial public offering price may differ
from the market price of our Ordinary Shares after the offering. As a result, you may not be able to sell your Ordinary Shares at